Salmeterol

• Description:

  Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].

• Product Name Alternative:

  GR33343X

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Field of Research:

  Endocrinology; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Salmeterol.html

• Purity:

  99.69

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  OC1=CC=C (C (O) CNCCCCCCOCCCCC2=CC=CC=C2) C=C1CO

• Molecular Formula:

  C25H37NO4

• Molecular Weight:

  415.57

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Panayiotis A Procopiou, et al. The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. Bioorg Med Chem. 2011 Oct 15;19 (20) :6026-32.|[2]Malcolm Johnson. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002 Dec;110 (6 Suppl) :S282-90.|[3]Zhiyuan Wang, et al. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp Ther Med. 2018 Feb;15 (2) :1538-1545.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  β adrenergic receptor

• Citation 01:

  Cell Rep. 2019 Dec 3;29 (10) :2929-2935.e4|Drug Test Anal. 2021 Feb;13 (2) :283-298.|J Pharm Anal. 2024 Jul;14 (7) :100934.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Nat Commun. 2020 Sep 25;11 (1) :4857.|Neuron. 2024 Jul 25:S0896-6273 (24) 00494-X.|Mol Ther. 2025 May 8:S1525-0016 (25) 00382-X.|Neurobiol Dis. 2020 Jul;140:104874.

• CAS Number:

  89365-50-4